| 2025-11-13 |
复牌提示：
2025-11-12 15:28:19 停牌，复牌日期 2025-11-12 15:33:19
|
| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.85美元,归母净利润-3538.1万美元,同比去年增长32.42%
|
| 2025-11-03 |
股东大会：
将于2025-12-15召开股东大会
会议内容 ▼▲
- 1.Approval of Authorized Share Increase Proposal. To consider and vote upon a proposal, which we refer to as the “First Charter Amendment,” to amend the Company’s Fourth Amended and Restated Certificate of Incorporation (the “Charter”) to increase the number of shares that the Company is authorized to issue from two hundred fifty million (250,000,000) shares to five hundred million (500,000,000) shares, of which four hundred ninety million (490,000,000) shall be designated as common stock, $0.001 par value per share (“Common Stock”) and to include clarifying language regarding the applicability of recently amended provisions of Section 242 of the Delaware General Corporation Law (the “DGCL”) (the “Authorized Share Increase Proposal”).
2.Approval of Reverse Stock Split Proposal. To approve an amendment to the Charter to permit the Board, in its discretion, to effect a reverse stock split of our Common Stock in a ratio to be determined, within a range of 1 to 5 (1:5) up to 1 to 20 (1:20), to allow the Company to regain compliance with Nasdaq listing requirements for the bid price of the Common Stock, to be effected in the sole discretion of the Board at any time within one year of the date of the Special Meeting without further approval or authorization from the Company’s stockholders (the “Reverse Stock Split Proposal”);
3.Approval of Equity Incentive Plan. To approve the Leap Therapeutics, Inc. 2025 Equity Incentive Plan (the “2025 EIP”) (the “EIP Proposal”).
4.Approval of Private Placement Issuance Proposal. To permit the Company, for the purpose of complying with Nasdaq Listing Rule 5635, to issue shares in excess of 19.99% of the Company’s outstanding Common Stock upon the exercise of certain warrants issued to purchasers in the Financing Transaction, which issuance, if it were to occur, would be considered a “change of control” under Nasdaq rules (the “Private Placement Issuance Proposal”).
5.A proposal to adjourn the Special Meeting if the Special Meeting is convened and a quorum is present, but there are not sufficient votes to approve any of the other proposals, so that our proxy holders may move to continue, adjourn or postpone the special meeting at that time in order to enable our Board to solicit additional proxies (the “Adjournment Proposal”, and, together with the Authorized Share Increase Proposal, the Reverse Stock Split Proposal, the EIP Proposal, and the Private Placement Issuance Proposal, the “Stockholder Proposals”).
|
| 2025-10-09 |
详情>>
股本变动：
变动后总股本5665.18万股
变动原因 ▼▲
- 原因：
- Common Stock offered 15,212,311 shares by the company
|
| 2025-08-14 |
详情>>
业绩披露：
2025年中报每股收益-0.78美元,归母净利润-3207.8万美元,同比去年增长6.16%
|
| 2025-05-13 |
详情>>
业绩披露：
2025年一季报每股收益-0.37美元,归母净利润-1543.5万美元,同比去年增长-11.69%
|
| 2025-04-28 |
股东大会：
将于2025-06-18召开股东大会
会议内容 ▼▲
- 1.To elect three Class II directors nominated by the Company’s board of directors (the “Board”), Thomas Dietz, William Li, and Patricia Martin, each to serve for a term ending in 2028, or until his or her successor has been duly elected and qualified;
2.To approve an advisory vote on executive compensation paid to our named executive officers (the “Say-on-Pay Proposal”);
3.To ratify the appointment of EisnerAmper LLP, an independent registered public accounting firm, as our independent auditors for the year ending December 31, 2025;
4.To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2025-03-28 |
详情>>
内部人交易：
Mirabelli Christopher等共交易11笔
|
| 2025-03-26 |
详情>>
业绩披露：
2024年年报每股收益-1.81美元,归母净利润-6778.9万美元,同比去年增长16.74%
|
| 2024-11-13 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.44美元,归母净利润-5235.8万美元,同比去年增长24.06%
|
| 2024-08-12 |
详情>>
业绩披露：
2024年中报每股收益-1.01美元,归母净利润-3418.2万美元,同比去年增长38.14%
|
| 2024-05-13 |
详情>>
业绩披露：
2024年一季报每股收益-0.51美元,归母净利润-1382万美元,同比去年增长66.99%
|
| 2024-04-29 |
股东大会：
将于2024-07-02召开股东大会
会议内容 ▼▲
- 1.To elect four Class I directors nominated by the Company’s board of directors (the “Board”), James Cavanaugh, Douglas E. Onsi, Christian Richard and Richard Schilsky, each to serve for a term ending in 2027, or until his successor has been duly elected and qualified;
2.To approve an advisory vote on executive compensation paid to our named executive officers (the “Say-on-Pay Proposal”);
3.To approve an amendment (the “2022 EIP Amendment”) to the Leap Therapeutics, Inc. 2022 Equity Incentive Plan (the “2022 EIP”) (the “EIP Proposal”);
4.To ratify the appointment of EisnerAmper LLP, an independent registered public accounting firm, as our independent auditors for the year ending December 31, 2024;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2024-03-18 |
详情>>
业绩披露：
2023年年报每股收益-3.98美元,归母净利润-8141.4万美元,同比去年增长-49.12%
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-3.78美元,归母净利润-6894.9万美元,同比去年增长-62.26%
|
| 2023-08-14 |
详情>>
业绩披露：
2023年中报每股收益-4.01美元,归母净利润-5525.3万美元,同比去年增长-101.65%
|
| 2023-06-21 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2023-04-28 |
股东大会：
将于2023-06-16召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors nominated by the Company’s board of directors (the “Board”), Joseph Loscalzo, Nissim Mashiach, and Christopher Mirabelli, each to serve for a term ending in 2026, or until his successor has been duly elected and qualified;
2.To approve an advisory vote on executive compensation paid to our named executive officers (the “Say-on-Pay Proposal”);
3.To indicate, on an advisory basis, the preferred frequency of future stockholder advisory votes on executive compensation (the “Say-on-Frequency Proposal”);
4.To approve an amendment (the “2022 EIP Amendment”) to the Leap Therapeutics, Inc. 2022 Equity Incentive Plan (the “2022 EIP”) (the “EIP Proposal”);
5.To ratify the appointment of EisnerAmper LLP, an independent registered public accounting firm, as our independent auditors for the year ending December 31, 2023;
6.To approve, in accordance with Nasdaq Listing Rule 5635(a), the issuance of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), upon conversion of the Company’s Series X Non-Voting Convertible Preferred Stock, par value $0.001 per share (the “Series X Preferred Stock”), issued in January 2023 (the “Conversion Proposal”);
7.To approve an amendment to the Restated Certificate of Incorporation to effect a reverse stock split of the Common Stock at a ratio to be determined by the within a range of one-for-five (1:5) and one-for-twenty (1:20) (or any number in between), to be effected in the sole discretion of the Board at any time within one year of the date of the Annual Meeting without further approval or authorization from the Company’s stockholders (the “Reverse Stock Split Proposal”);
8.To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.
|
| 2022-04-28 |
股东大会：
将于2022-06-16召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors nominated by our board of directors, William Li, MD and Thomas Dietz, PhD, each to serve for a term ending in 2025, or until his successor has been duly elected and qualified;
2.To approve the Leap Therapeutics, Inc. 2022 Equity Incentive Plan (“2022 EIP”);
3.To ratify the appointment of EisnerAmper LLP, an independent registered public accounting firm, as our independent auditors for the year ending December 31, 2022;
4.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-28 |
股东大会：
将于2021-06-15召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors nominated by our board of directors, Monica Bertagnolli, MD, FASCO, James Cavanaugh, PhD and Douglas E. Onsi, each to serve for a term ending in 2024, or until his or her successor has been duly elected and qualified;
2.To ratify the appointment of EisnerAmper LLP, an independent registered public accounting firm, as our independent auditors for the year ending December 31, 2021;
3.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2020-06-11 |
股东大会：
将于2020-06-16召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors nominated by our board of directors, Joseph Loscalzo, MD, PhD, Nissim Mashiach, and Christopher K. Mirabelli, PhD, each to serve for a term ending in 2023, or until his successor has been duly elected and qualified;
2.To ratify the appointment of EisnerAmper LLP, an independent registered public accounting firm, as our independent auditors for the year ending December 31, 2020;
3.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2020-02-10 |
股东大会：
将于2020-03-05召开股东大会
会议内容 ▼▲
- 1.Approval of Charter Amendment. To consider and vote upon a proposal, which we refer to as the "Charter Amendment," to amend the Company's Third Amended and Restated Certificate of Incorporation (the "Charter") to increase the number of shares of Common Stock that the Company is authorized to issue from one hundred ten million (110,000,000) shares to two hundred fifty million (250,000,000) shares.
2.Approval of Private Placement Issuance Proposal. To consider and vote upon a proposal, which we refer to as the "Private Placement Issuance Proposal," to issue (1) Common Stock and Pre-Funded Warrants, as applicable, upon the conversion of the Mandatorily Convertible Preferred Stock, (2) Coverage Warrants upon the conversion of the Mandatorily Convertible Preferred Stock, and (3) Common Stock upon the exercise of the Pre-Funded Warrants and the Coverage Warrants, in each case for purposes of Rule 5635 of the Nasdaq Stock Market Rules.
3.Authorization to Adjourn the Special Meeting. If the Special Meeting is convened and a quorum is present, but there are not sufficient votes to approve Proposals 1 and 2, our proxy holders may move to continue, adjourn or postpone the Special Meeting at that time in order to enable our board of directors to solicit additional proxies, which we refer to as the "Adjournment Proposal."
|
| 2019-04-29 |
股东大会：
将于2019-06-11召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors nominated by our board of directors, William Li and Thomas Dietz, each to serve for a term ending in 2022, or until his successor has been duly elected and qualified;
2.To ratify the appointment of EisnerAmper LLP, an independent registered public accounting firm, as our independent auditors for the year ending December 31, 2019;
3.To approve the First Amendment to the 2016 Equity Incentive Plan to increase the number of shares reserved for issuance under the plan by 3,000,000 shares;
4.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2018-03-16 |
股东大会：
将于2018-05-03召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors nominated by our board of directors, James Cavanaugh and John Littlechild, each to serve for a term ending in 2021, or until his successor has been duly elected and qualified;
2.To ratify the appointment of EisnerAmper LLP, an independent registered public accounting firm, as our independent auditors for the year ending December 31, 2018;
3.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2017-12-19 |
股东大会：
将于2018-01-12召开股东大会
会议内容 ▼▲
- 1.Approval of Full Ratchet Anti-Dilution Protection Included in Warrants. To consider and vote upon a proposal, which we refer to as the "Anti-Dilution Approval Proposal," to approve the full ratchet anti-dilution protection provisions included in the Warrants issued in connection with the Company's entry into purchase agreements (each, a "Purchase Agreement", and collectively, the "Purchase Agreements") on November 14, 2017 with certain existing and new institutional accredited Purchasers (collectively, the "Purchasers") pursuant to which the Company, agreed to issue and sell to the Purchasers an aggregate of 2,958,094 shares (the "Shares") of unregistered common stock of the Company, par value $0.001 per share (the "Common Stock"), at a price per share of $6.085, each share issued with a warrant (each, a "Warrant", and collectively, the "Warrants") to purchase one share of Common Stock (the "Warrant Shares") at an exercise price of $6.085 (the "Exercise Price") with an exercise period expiring seven years after closing (the "Term"), for gross proceeds of approximately $18.0 million (the "Private Placement").
|